- Home
- UNB vs ZNTL Comparison
UNB vs ZNTL Comparison
Compare UNB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- ZNTL
- Stock Information
- Founded
- UNB 1891
- ZNTL 2014
- Country
- UNB United States
- ZNTL United States
- Employees
- UNB N/A
- ZNTL N/A
- Industry
- UNB Major Banks
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- UNB Finance
- ZNTL Health Care
- Exchange
- UNB Nasdaq
- ZNTL Nasdaq
- Market Cap
- UNB 99.3M
- ZNTL 118.3M
- IPO Year
- UNB 1998
- ZNTL 2020
- Fundamental
- Price
- UNB $22.99
- ZNTL $1.39
- Analyst Decision
- UNB
- ZNTL Buy
- Analyst Count
- UNB 0
- ZNTL 7
- Target Price
- UNB N/A
- ZNTL $6.17
- AVG Volume (30 Days)
- UNB 11.1K
- ZNTL 696.6K
- Earning Date
- UNB 11-10-2025
- ZNTL 11-10-2025
- Dividend Yield
- UNB 6.21%
- ZNTL N/A
- EPS Growth
- UNB 27.30
- ZNTL N/A
- EPS
- UNB 2.47
- ZNTL N/A
- Revenue
- UNB $52,533,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- UNB N/A
- ZNTL N/A
- Revenue Next Year
- UNB N/A
- ZNTL N/A
- P/E Ratio
- UNB $9.40
- ZNTL N/A
- Revenue Growth
- UNB 13.25
- ZNTL N/A
- 52 Week Low
- UNB $20.65
- ZNTL $1.01
- 52 Week High
- UNB $37.70
- ZNTL $4.00
- Technical
- Relative Strength Index (RSI)
- UNB 48.98
- ZNTL 48.04
- Support Level
- UNB $21.50
- ZNTL $1.30
- Resistance Level
- UNB $23.33
- ZNTL $1.39
- Average True Range (ATR)
- UNB 0.72
- ZNTL 0.09
- MACD
- UNB 0.09
- ZNTL 0.01
- Stochastic Oscillator
- UNB 80.17
- ZNTL 85.92
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.